Search Results - "Roveta, A."

Updated report of an observational clinical registry (REGCLIN-MM) on malignant pleural mesothelioma (MPM) by Grosso, F., Ceresoli, G.L., Roveta, A., Bearz, A., Valentino, F., Novello, S., Santoro, A., Cognetti, F., Amadori, D., Dall'olio, F.G., Zucchi, L., Pastorino, U., Rea, F., Boni, C., Maggioni, P., Gallizzi, G., Maconi, A., Scagliotti, G.V., Magnani, C.

Get full text

9146 POSTER Sarcomatoid Malignant Pleural Mesothelioma – a Series of 44 Cases Treated at a Single Oncological Department by Grosso, F, Botta, M, Degiovanni, D, Florio, F, Roveta, A, Libener, R, Piccolini, E, Franzone, P, Bottero, G, Betta, R.G

Get full text

SAKK 17/16 - Lurbinectedin as second or third line palliative chemotherapy in malignant pleural mesothelioma (MPM): A multi-center, single-arm phase II trial by Metaxas, Y., Frueh, M., Eboulet, E.I., Grosso, F., Pless, M., Zucali, P.A., Ceresoli, G.L., Mark, M.T., Schneider, M., Roveta, A., Perrino, M.R.A., Biaggi Rudolf, C., Froesch, P.R., Schmidt, S., Waibel, C., Appenzeller, C., Rauch, D., von Moos, R.

Get full text

1843O - SAKK 17/16 - Lurbinectedin as second or third line palliative chemotherapy in malignant pleural mesothelioma (MPM): A multi-center, single-arm phase II trial by Metaxas, Y., Frueh, M., Eboulet, E.I., Grosso, F., Pless, M., Zucali, P.A., Ceresoli, G.L., Mark, M.T., Schneider, M., Roveta, A., Perrino, M.R.A., Biaggi Rudolf, C., Froesch, P.R., Schmidt, S., Waibel, C., Appenzeller, C., Rauch, D., von Moos, R.

“…Available systemic 2nd or 3rd line options for MPM show a median progression-free survival (mPFS) of less than 2 months (mo) and median overall-survival (mOS)…”
Get full text

Frequency and intensity of symptoms and disease awareness in a large mono-institutional series of Malignant Pleural Mesothelioma (MPM) patients followed within a simultaneous care program by Gallizzi, G., Grosso, F., Kasa, A., Oneglia, B., Ballarino, P., Roveta, A., Giaretto, L., Muzio, A., Numico, G., Degiovanni, D.

Get full text

1843OSAKK 17/16 - Lurbinectedin as second or third line palliative chemotherapy in malignant pleural mesothelioma (MPM): A multi-center, single-arm phase II trial by Metaxas, Y, Frueh, M, Eboulet, E I, Grosso, F, Pless, M, Zucali, P A, Ceresoli, G L, Mark, M T, Schneider, M, Roveta, A, Perrino, M R A, Biaggi Rudolf, C, Froesch, P R, Schmidt, S, Waibel, C, Appenzeller, C, Rauch, D, von Moos, R

“…Abstract Background Available systemic 2nd or 3rd line options for MPM show a median progression-free survival (mPFS) of less than 2 months (mo) and median…”
Get full text

Frequency, patterns and prognostic impact of distant metastases in a large mono-institutional series of malignant pleural mesothelioma (MPM): Not necessarily bad news by Grosso, F., Roveta, A., Gallizzi, G., Muzio, A., Zai, S., Ugo, F., Aurelio, A., Libener, R., Mancuso, M., Ferretti, G., Franzone, P., Pastormerlo, M., Piccolini, E., Degiovanni, D., Numico, G.

Get full text

Prevalence, Clinical Features and Prognosis of Diffuse Malignant Peritoneal Mesothelioma (DMPM): Do Patients in Clinical Trials Reflect the real World? by Grosso, F., Degiovanni, D., Roveta, A., Barbero, S., Libener, R., Musante, F., Testori, O., Mirabelli, D., Betta, P.G., Botta, M.

Get full text

Long-term survivors (LS) of malignant pleural mesothelioma (MPM): An effort to gain knowledge of this uncommon biology by Grosso, F., Roveta, A., Bensi, T., Trincheri, N. F., Libener, R., Pavesi, M., Giaretto, L., Piccolini, E., Botta, M., Bottero, G., Mirabelli, D., Betta, P. G.

“…Abstract only…”
Get full text